drugset / Trial / NCT05085197
The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different doses and dose-matched placebo were administered under fasted conditions.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2022-04-05
- Completion
- 2022-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STSA-1005 | Unknown | 1 mg/kg | Intravenous |
| Subject | STSA-1005 | Unknown | 2.5 mg/kg | Intravenous |
| Subject | STSA-1005 | Unknown | 5 mg/kg | Intravenous |
| Subject | STSA-1005 | Unknown | 10 mg/kg | Intravenous |
Indications
No indication recorded.